Genes and Development

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Published online before print January 31, 2003, 10.1101/gad.1054703
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
U-10547Rspv1
17/4/449    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cichowski, K.
Right arrow Articles by Jacks, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cichowski, K.
Right arrow Articles by Jacks, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Vol. 17, No. 4, pp. 449-454, February 15, 2003

RESEARCH COMMUNICATION
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor

Karen Cichowski,1,4 Sabrina Santiago,2 Melanie Jardim,1 Bryan W. Johnson,1 and Tyler Jacks2,3

1 Genetics Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA; 2 Department of Biology, Center for Cancer Research, and 3 Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Mutations in the NF1 tumor suppressor underlie the familial tumor predisposition syndrome neurofibromatosis type I. Although its encoded protein, neurofibromin, functions as a Ras-GTPase activating protein (GAP), nothing is known about how it is normally regulated or its precise role in controlling Ras signaling pathways. We show here that neurofibromin is dynamically regulated by the ubiquitin-proteasome pathway. Degradation is rapidly triggered in response to a variety of growth factors and requires sequences adjacent to the catalytic GAP-related domain of neurofibromin. However, whereas degradation is rapid, neurofibromin levels are re-elevated shortly after growth factor treatment. Accordingly, Nf1-deficient mouse embryonic fibroblasts (MEFs) exhibit an enhanced activation of Ras, prolonged Ras and ERK activities, and proliferate in response to subthreshold levels of growth factors. Thus, the dynamic proteasomal regulation of neurofibromin represents an important mechanism of controlling both the amplitude and duration of Ras-mediated signaling. Furthermore, this previously unrecognized Ras regulatory mechanism may be exploited therapeutically.

[Keywords: NF1; signal transduction; tumor suppressor; Ras; proteasome]

4 Corresponding author.

© 2003 by Cold Spring Harbor Laboratory Press  ISSN 0890-9369/03 $5.00
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
G. C. Daginakatte and D. H. Gutmann
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth
Hum. Mol. Genet., May 1, 2007; 16(9): 1098 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Barkan, S. Starinsky, E. Friedman, R. Stein, and Y. Kloog
The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1.
Clin. Cancer Res., September 15, 2006; 12(18): 5533 - 5542.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. M. Munchhof, F. Li, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, X. Li, J. Yuan, F.-C. Yang, and D. A. Ingram
Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells
Hum. Mol. Genet., June 1, 2006; 15(11): 1858 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W.-M. Yu, H. Daino, J. Chen, K. D. Bunting, and C.-K. Qu
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling
J. Biol. Chem., March 3, 2006; 281(9): 5426 - 5434.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. T. Efuet and K. Keyomarsi
Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome
Cancer Res., January 15, 2006; 66(2): 1040 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
K. E. Yutzey, M. Colbert, and J. Robbins
Ras-Related Signaling Pathways in Valve Development: Ebb and Flow
Physiology, December 1, 2005; 20(6): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. M. Johannessen, E. E. Reczek, M. F. James, H. Brems, E. Legius, and K. Cichowski
The NF1 tumor suppressor critically regulates TSC2 and mTOR
PNAS, June 14, 2005; 102(24): 8573 - 8578.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. T. Le, N. Kong, Y. Zhu, J. O. Lauchle, A. Aiyigari, B. S. Braun, E. Wang, S. C. Kogan, M. M. Le Beau, L. Parada, et al.
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder
Blood, June 1, 2004; 103(11): 4243 - 4250.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
D. Lallemand, M. Curto, I. Saotome, M. Giovannini, and A. I. McClatchey
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
Genes & Dev., May 1, 2003; 17(9): 1090 - 1100.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Genome Res. Learn. Mem.
Protein Science RNA Genes Dev.